Afrezza 180 Inhalation Cartridge Titration Pack - 60 (4 UNT), 60 (8 UNT), 60 (12 UNT)
RxNorm 1862102

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1862102 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: afrezza 180 Inhalation Cartridge Titration Pack - 60 (4 UNT), 60 (8 UNT), 60 (12 UNT).

The following semantic concepts and normalized strings are associated with this clinical entity:

PSN
Afrezza 180 Inhalation Cartridge Titration Pack - 60 (4 UNT), 60 (8 UNT), 60 (12 UNT)
AUI:8705104
SY
Afrezza 180 Inhalation Cartridge Titration Pack - 60 (4 UNT), 60 (8 UNT), 60 (12 UNT)
AUI:8705105
BPCK
{60 (insulin, regular, human 12 UNT Inhalation Powder [Afrezza]) / 60 (insulin, regular, human 4 UNT Inhalation Powder [Afrezza]) / 60 (insulin, regular, human 8 UNT Inhalation Powder [Afrezza]) } Pack [Afrezza 180 Titration Pack- 60 (4 UNT), 60 (8 UNT), 60 (12 UNT)]
AUI:11795419

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

PSNPrescribable

Prescribable Name (PSN):
Afrezza 180 Inhalation Cartridge Titration Pack - 60 (4 UNT), 60 (8 UNT), 60 (12 UNT)
(Atom ID: 8705104)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
afrezza 180 Inhalation Cartridge Titration Pack - 60 (4 UNT), 60 (8 UNT), 60 (12 UNT)
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1862102
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
8705104
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
1862102
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

SYPrescribable

Synonym (SY):
Afrezza 180 Inhalation Cartridge Titration Pack - 60 (4 UNT), 60 (8 UNT), 60 (12 UNT)
(Atom ID: 8705105)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Afrezza 180 Inhalation Cartridge Titration Pack - 60 (4 UNT), 60 (8 UNT), 60 (12 UNT)
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1862102
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
8705105
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
1862102
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

BPCKPrescribable

Brand Name Pack (BPCK):
{60 (insulin, regular, human 12 UNT Inhalation Powder [Afrezza]) / 60 (insulin, regular, human 4 UNT Inhalation Powder [Afrezza]) / 60 (insulin, regular, human 8 UNT Inhalation Powder [Afrezza]) } Pack [Afrezza 180 Titration Pack- 60 (4 UNT), 60 (8 UNT), 60 (12 UNT)]
(Atom ID: 11795419)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
{60 (insulin, regular, human 12 UNT Inhalation Powder [Afrezza]) / 60 (insulin, regular, human 4 UNT Inhalation Powder [Afrezza]) / 60 (insulin, regular, human 8 UNT Inhalation Powder [Afrezza]) } Pack [Afrezza 180 Titration Pack- 60 (4 UNT), 60 (8 UNT), 60 (12 UNT)]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1862102
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
11795419
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
BPCK
Brand Name Pack ({# (Ingredient Strength Dose Form) / # (Ingredient Strength Dose Form)} Pack [Brand Name])
Source Code
1862102
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN HUMAN DRUG
US
Drug available for use in Humans

Patient Education

Insulin Human Inhalation


Insulin inhalation is used in combination with a long-acting insulin to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also used in combination with other medications to treat people with type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in the blood) who need insulin to control their diabetes. Insulin inhalation is not used for the treatment diabetic ketoacidosis (a serious condition that may develop if high blood sugar is not treated). Insulin inhalation is a short-acting, man-made version of human insulin. Insulin inhalation works by replacing the insulin that is normally produced by the body and by helping to move sugar from the blood into other body tissues where it is used for energy. It also stops the liver from producing more sugar. Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Using medication(s), making lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking your blood sugar may help to manage your diabetes and improve your health. This therapy may also decrease your chances of having a heart attack, stroke, or other diabetes-related complications such as kidney failure, nerve damage (numb, cold legs or feet; decreased sexual ability in men and women), eye problems, including changes or loss of vision, or gum disease. Your doctor and other healthcare providers will talk to you about the best way to manage your diabetes.
[Learn More]


* Please review the disclaimer below.